{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:23:49Z","timestamp":1792700629422,"version":"4.5.0"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1749,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1111\/j.1365-2036.2010.04512.x","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T02:56:28Z","timestamp":1290048988000},"page":"235-242","source":"Crossref","is-referenced-by-count":165,"title":["Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid"],"prefix":"10.1111","volume":"33","author":[{"given":"C.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Keach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Petz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Firpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Soldevila-Pico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,17]]},"reference":[{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","article-title":"Primary biliary cirrhosis","volume":"9377","author":"Talwalkar","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB10|cit10","first-page":"1518","article-title":"A novel treatment for refractory primary biliary cirrhosis?","volume":"47","author":"Miyaguchi","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","article-title":"Effect of bezafibrate in primary biliary cirrhosis: a pilot study","volume":"21","author":"Ohmoto","year":"2001","journal-title":"Liver"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","author":"Yano","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","article-title":"Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"49","author":"Walker","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0014-5793(92)80734-X","article-title":"Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver","volume":"309","author":"Gebel","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2008.03.007","article-title":"PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes","volume":"231","author":"Thulin","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","article-title":"Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels","volume":"41","author":"Kita","year":"2006","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s005350300053","article-title":"Efficacy of bezafibrate in a patient with primary sclerosing cholangitis","volume":"38","author":"Kurihara","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1172\/JCI118118","article-title":"Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor","volume":"96","author":"Vu-Dac","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.4049\/jimmunol.172.9.5790","article-title":"Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease","volume":"172","author":"Lovett-Racke","year":"2004","journal-title":"J Immunol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5551\/jat.9.87","article-title":"Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats","volume":"9","author":"Maruyama","year":"2002","journal-title":"J Atheroscler Thromb"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2007.03.113","article-title":"Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice","volume":"133","author":"Lee","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00228-003-0704-1","article-title":"Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients","volume":"59","author":"Roglans","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1365-2036.2010.04512.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.hepres.2004.08.015","article-title":"Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate","volume":"30","author":"Matsumoto","year":"2004","journal-title":"Hepatol Res"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04512.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2010.04512.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T18:34:50Z","timestamp":1636828490000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04512.x"}},"subtitle":["Pilot study: fenofibrate with UDCA for primary biliary cirrhosis"],"short-title":[],"issued":{"date-parts":[[2010,11,17]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04512.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,17]]}}}